PMID- 19388937
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20151119
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 145
IP  - 6
DP  - 2009 Jun
TI  - Beta2-microglobulin is a better predictor of treatment-free survival in patients 
      with chronic lymphocytic leukaemia if adjusted according to glomerular filtration 
      rate.
PG  - 801-5
LID - 10.1111/j.1365-2141.2009.07699.x [doi]
AB  - Even in the era of newer and sophisticated prognostic markers, 
      beta(2)-microglobulin (B2M) remains a simple but very powerful predictor of 
      treatment-free survival (TFS) and overall survival (OS) in patients with chronic 
      lymphocytic leukaemia (CLL). However, B2M levels are heavily influenced by the 
      patient's glomerular filtration rate (GFR) and this study aimed to evaluate 
      whether GFR-adjusted B2M (GFR-B2M) had improved prognostic value compared to 
      unadjusted B2M in a cohort of over 450 consecutive CLL patients from two separate 
      institutions. Multivariate analysis identified a significantly shorter TFS in 
      patients who were ZAP-70 + (P < 0.001), with increased GFR-B2M (P < 0.001), and 
      del(11q) or del(17p) as detected by fluorescence in situ hybridization (FISH; P < 
      0.001). When OS was evaluated by multivariate analysis, age 65 years or older (P 
      < 0.001) and poor risk FISH abnormalities (P < 0.001) had a confirmed adverse 
      prognostic impact, but the predictive value of GFR-B2M was lost in the validation 
      analysis. In all survival models, B2M did not attain independent significance 
      unless GFR-B2M was eliminated from the analysis. In conclusion, GFR-B2M is a 
      better predictor of TFS than unadjusted B2M in CLL patients.
FAU - Delgado, Julio
AU  - Delgado J
AD  - Department of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain. jdelgadog@santpau.cat
FAU - Pratt, Guy
AU  - Pratt G
FAU - Phillips, Neil
AU  - Phillips N
FAU - Briones, Javier
AU  - Briones J
FAU - Fegan, Chris
AU  - Fegan C
FAU - Nomdedeu, Josep
AU  - Nomdedeu J
FAU - Pepper, Chris
AU  - Pepper C
FAU - Aventin, Anna
AU  - Aventin A
FAU - Ayats, Ramon
AU  - Ayats R
FAU - Brunet, Salut
AU  - Brunet S
FAU - Martino, Rodrigo
AU  - Martino R
FAU - Valcarcel, David
AU  - Valcarcel D
FAU - Milligan, Donald
AU  - Milligan D
FAU - Sierra, Jorge
AU  - Sierra J
LA  - eng
PT  - Journal Article
DEP - 20090415
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (beta 2-Microglobulin)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Creatinine/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*blood/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Survival Rate
MH  - beta 2-Microglobulin/*blood
EDAT- 2009/04/25 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/04/25 09:00
PHST- 2009/04/25 09:00 [entrez]
PHST- 2009/04/25 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - BJH7699 [pii]
AID - 10.1111/j.1365-2141.2009.07699.x [doi]
PST - ppublish
SO  - Br J Haematol. 2009 Jun;145(6):801-5. doi: 10.1111/j.1365-2141.2009.07699.x. Epub 
      2009 Apr 15.